| Literature DB >> 32359879 |
Ming-Lung Yu1, Pei-Jer Chen2, Chia-Yen Dai3, Tsung-Hui Hu4, Chung-Feng Huang3, Yi-Hsiang Huang5, Chao-Hung Hung4, Chun-Yen Lin6, Chen-Hua Liu7, Chun-Jen Liu2, Cheng-Yuan Peng8, Han-Chieh Lin9, Jia-Horng Kao2, Wan-Long Chuang3.
Abstract
Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.Entities:
Keywords: Consensus; DAA; HCV; TASL; Taiwan
Mesh：
Substances：
Year: 2020 PMID： 32359879 DOI： 10.1016/j.jfma.2020.04.003
Source DB: PubMed Journal: J Formos Med Assoc ISSN： 0929-6646 Impact factor: 3.282